Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CATX | PRESS-RELEASE | neutral | 4/10 | Perspective Therapeutics announced it will present updated data on three clinical-stage programs ([²¹²Pb]VMT-α-NET, [²¹² | May 21, 2026 |
| ZNTL | PRESS-RELEASE | bullish | 6/10 | Zentalis announced positive Phase 1b data for azenosertib plus paclitaxel in platinum-resistant ovarian cancer, with 39% | May 21, 2026 |
| VCIG | PRESS-RELEASE | bearish | 6/10 | VCI Global disclosed receiving a Nasdaq late-filing notice for its FY2025 Form 20-F. The company previously filed a Form | May 21, 2026 |
| NOA | PRESS-RELEASE | neutral | 2/10 | North American Construction Group held its Annual and Special Meeting on May 20, 2026. Shareholders elected directors, r | May 21, 2026 |
| EQS | PRESS-RELEASE | bullish | 5/10 | Equus Total Return reported Q1 2026 net assets of $20.9M ($1.50/share) vs $16.6M ($1.19/share) at Dec 31, 2025, a 26% se | May 21, 2026 |
| AUTL | PRESS-RELEASE | neutral | 4/10 | Autolus Therapeutics released a post-hoc analysis of the Phase Ib/II FELIX study for ASCO, showing obe-cel achieved a 59 | May 21, 2026 |
| BDTX | PRESS-RELEASE | bullish | 8/10 | Black Diamond Therapeutics reported positive Phase 2 results for silevertinib in frontline NSCLC with EGFR non-classical | May 21, 2026 |
| AKTS | PRESS-RELEASE | bullish | 7/10 | Aktis reported first-in-human clinical imaging and dosimetry data for AKY-2519, a B7-H3-targeted miniprotein radioconjug | May 21, 2026 |
| REGN | PRESS-RELEASE | bullish | 6/10 | Regeneron announced positive Phase 1/2 LINKER-AL2 results for Lynozyfic (linvoseltamab) in second-line-plus systemic AL | May 21, 2026 |
| CMPX | PRESS-RELEASE | bullish | 7/10 | Compass Therapeutics announced a poster presentation at ASCO 2026 showing Phase 1 dose-escalation data for CTX-8371, a P | May 21, 2026 |
| OLMA | PRESS-RELEASE | bullish | 6/10 | Olema Oncology announced preliminary Phase 1 data for OP-3136, a KAT6 inhibitor, showing acceptable tolerability and ear | May 21, 2026 |
| LEGN | PRESS-RELEASE | bullish | 7/10 | Legend Biotech announced multiple ASCO 2026 presentations, including a rapid oral presentation of preliminary Phase 1 da | May 21, 2026 |
| CRDF | PRESS-RELEASE | neutral | 4/10 | Cardiff Oncology announced it will present updated Phase 2 data for onvansertib in RAS-mutated mCRC at ASCO on June 2, 2 | May 21, 2026 |
| AMSC | PRESS-RELEASE | neutral | 1/10 | AMSC announced it will report its fiscal Q4 2025 and full-year results on May 27, 2026. | May 21, 2026 |
| CVBF | PRESS-RELEASE | neutral | 2/10 | CVB Financial Corp. announced a planned leadership transition, with George A. Borba Jr. succeeding Hal W. Oswalt as Chai | May 21, 2026 |
| SEER | PRESS-RELEASE | neutral | 5/10 | Seer's Board unanimously rejected a revised $2.40/share cash-plus-CVR takeover proposal from the Radoff-JEC Group, calli | May 21, 2026 |
| HUBG | PRESS-RELEASE, 8-K | bearish | 7/10 | Hub Group received a Nasdaq deficiency notice for failing to timely file its Q1 2026 10-Q. The company has until June 3 | May 21, 2026 |
| KAI | PRESS-RELEASE | neutral | 3/10 | Kadant announced a new $50 million share repurchase authorization expiring May 2027 and a $0.36 per share quarterly divi | May 21, 2026 |
| HUBG | PRESS-RELEASE | bearish | 7/10 | Hub Group disclosed a Nasdaq Listing Rule 5250(c)(1) non-compliance notice for failing to timely file its Q1 2026 Form 1 | May 21, 2026 |
| XE | PRESS-RELEASE | neutral | 1/10 | X-Energy, Inc. announced it will report its Q1 2026 results on June 4, 2026. | May 21, 2026 |
| ZM | PRESS-RELEASE | neutral | 5/10 | Zoom reported Q1 FY2027 revenue of $1.239B (+5.5% YoY) and GAAP EPS of $1.42, a 1.7% beat vs $1.42 consensus. Enterprise | May 21, 2026 |
| CVCO | PRESS-RELEASE | bullish | 6/10 | Cavco Industries reported Q4 FY2026 EPS of $5.42, a 2.3% beat vs the $5.30 consensus, on revenue of $550M (+8% YoY). The | May 21, 2026 |
| NGEN | PRESS-RELEASE | bearish | 5/10 | NervGen Pharma announced an underwritten public offering of common shares and warrants (including pre-funded warrants) t | May 21, 2026 |
| UNTY | PRESS-RELEASE | neutral | 2/10 | Unity Bancorp declared a quarterly cash dividend of $0.16 per share, payable June 18, 2026, to shareholders of record as | May 21, 2026 |
| VZ | PRESS-RELEASE | neutral | 3/10 | Verizon's Q1 2026 EPS of $1.28 slightly beat consensus of $1.27 by 0.5%, while revenue of $35.47B was in line. The press | May 21, 2026 |
| TVGN | PRESS-RELEASE | neutral | 4/10 | Tevogen Bio announced a non-binding Letter of Intent to evaluate a potential transaction with a Management Services Orga | May 21, 2026 |
| CBC | PRESS-RELEASE | neutral | 1/10 | Central Bancompany announced it will host a conference call to discuss its Q2 2026 results. | May 21, 2026 |
| CMBT | PRESS-RELEASE | neutral | 3/10 | CMB.TECH shareholders approved a distribution of $0.64 per share (minimum $130M, maximum $200M) from share premium, and | May 21, 2026 |
| ALP | PRESS-RELEASE | neutral | 4/10 | Alpha Compute provided a business update highlighting a $32.2M two-year contract ($16.1M annualized), the go-live of its | May 21, 2026 |
| DAIO | PRESS-RELEASE | mixed | 6/10 | Data I/O issued a corrected press release clarifying Q2 2026 revenue guidance of $5.0-5.4M, implying >50% sequential gro | May 21, 2026 |